Rafarma Pharmaceuticals Stock Probability of Future Pink Sheet Price Finishing Under 0.085
| RAFA Stock | USD 0.07 0.01 16.25% |
Rafarma |
Rafarma Pharmaceuticals Target Price Odds to finish below 0.085
The tendency of Rafarma Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 0.09 after 90 days |
| 0.07 | 90 days | 0.09 | about 65.1 |
Based on a normal probability distribution, the odds of Rafarma Pharmaceuticals to stay under $ 0.09 after 90 days from now is about 65.1 (This Rafarma Pharmaceuticals probability density function shows the probability of Rafarma Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Rafarma Pharmaceuticals price to stay between its current price of $ 0.07 and $ 0.09 at the end of the 90-day period is about 23.88 .
Given the investment horizon of 90 days Rafarma Pharmaceuticals has a beta of -0.86 indicating Moreover Rafarma Pharmaceuticals has an alpha of 1.2435, implying that it can generate a 1.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Rafarma Pharmaceuticals Price Density |
| Price |
Predictive Modules for Rafarma Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rafarma Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Rafarma Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rafarma Pharmaceuticals is not an exception. The market had few large corrections towards the Rafarma Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rafarma Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rafarma Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.24 | |
β | Beta against Dow Jones | -0.86 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | 0.07 |
Rafarma Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rafarma Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rafarma Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rafarma Pharmaceuticals is way too risky over 90 days horizon | |
| Rafarma Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Rafarma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rafarma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rafarma Pharmaceuticals generates negative cash flow from operations |
Rafarma Pharmaceuticals Technical Analysis
Rafarma Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Rafarma Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rafarma Pharmaceuticals. In general, you should focus on analyzing Rafarma Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Rafarma Pharmaceuticals Predictive Forecast Models
Rafarma Pharmaceuticals' time-series forecasting models is one of many Rafarma Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rafarma Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Rafarma Pharmaceuticals
Checking the ongoing alerts about Rafarma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rafarma Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Rafarma Pharmaceuticals is way too risky over 90 days horizon | |
| Rafarma Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Rafarma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rafarma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rafarma Pharmaceuticals generates negative cash flow from operations |
Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.